Many factors can affect the survival time of patients and need to be evaluated based on actual disease
Many early symptoms of gastric adenocarcinoma are not obvious and easily overlooked, and when diagnosed, they are often advanced and accompanied by metastases of different degrees.
For patients with gastric adenocarcinoma with metastasis, many factors such as the patient’s general condition, psychological status, the stage of the lesion, the nature of the pathology, the site of metastasis, and the response to treatment can affect the patient’s survival.
For patients with lymph node metastasis who can still undergo radical surgery, the median survival is between 20 and 60 months, with a 5-year survival rate between 40% and 80%, depending on the patient’s individual condition and response to treatment; for hypofractionated adenocarcinoma, with high malignancy, rapid disease progression, and a high chance of distant metastasis, the disease can still be treated surgically in the early stages, but the results of treatment in the late stages are not as good. The results are not as good as they should be.
The survival of patients with extensive metastases and unresectable lymph node involvement varies depending on the site of metastasis, with brain metastases generally having the shortest survival time and multi-organ metastases having a shorter survival time than single-organ metastases.
The liver is the most common site of metastasis in progressive gastric adenocarcinoma, with a 5-year survival rate of less than 10% and a median survival of 3 to 5 months without treatment; patients with brain metastases are severely ill and very poorly treated, with an expected survival of no more than 2 to 4 months.
The survival time of patients with adenocarcinoma with metastasis is influenced by many factors and is difficult to estimate accurately. Maintaining healthy lifestyle habits, proper diet, and regular medical checkups are the keys to preventing gastric cancer as well as early detection and treatment.